Pharmaceutical Technology on MSN17h
EC approves CSL’s Andembry to stop hereditary angioedema attacks
CSL has received approval from the European Commission (EC) for Andembry (garadacimab) to prevent recurrent attacks of ...
pharmaphorum1d
EU approves CSL's once-monthly HAE drug Andembry
CSL has been given approval by the European Commission for Andembry, the first once-monthly preventive therapy for the ...
PharmaTimes2d
Andembry treatment approved across Europe
Global biotechnology leader CSL has announced that the European Commission (EC) has approved ANDEMBRY (garadacimab), the ...
The Pharma Letter1d
EC approves CSL’s Andembry
The European Commission (EC) has approved Andembry (garadacimab), the first and only once-monthly treatment targeting factor XIIa to prevent attacks of hereditary angioedema (HAE) in adult and ...
PMLive12d
MHRA approves CSL’s Andembry to treat angioedema attacks in HAE patients
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved CSL’s Andembry (garadacimab) to prevent ...
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that the European Commission (EC) has approved ...
BioWorld17d
TGA clears CSL’s garadacimab to prevent hereditary angioedema
Australia’s Therapeutic Goods Administration (TGA) has approved CSL Ltd.’s Andembry (garadacimab) for preventing recurrent hereditary angioedema attacks, marking the first global approval for the drug ...
The Age22d
Their arms, legs and throats start randomly swelling. Then scientists ‘engineered’ a precision treatment
The drug, Andembry, is a thoroughly modern medicine: it contains an engineered antibody, grown in a lab and precisely designed via computer and painstaking experiments. “With an antibody’s ...
CSL projects 10-13% NPATA growth for fiscal 2025 amid strong Behring performance and Seqirus recovery plans
Q2 2025 Management View CEO Paul McKenzie announced a reaffirmation of guidance for fiscal 2025, targeting NPATA growth of 10% to 13%. He highlighted strong results from CSL Behring and growth in CSL ...
PMLive1d
EC approves CSL’s Andembry to prevent hereditary angioedema attacks
The European Commission (EC) has approved CSL’s Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE) in ...